Chronic Chagas disease and type 2 diabetes comorbidity. The scenario in which two differently driven inflammatory mechanisms meet.

Chagas disease (ChD) and Type 2 diabetes (T2D) originate from distinct etiological processes -infectious and metabolic, respectively- yet both share a chronic inflammatory and metabolic imbalance that profoundly impacts immune-endocrine homeostasis. Persistent Trypanosoma cruzi infection in ChD induces sustained immune activation, altered adrenal steroid balance, and tissue remodeling, whereas T2D is characterized by metabolic inflammation, oxidative stress, and insulin resistance. When these two conditions coexist, their overlapping inflammatory, metabolic, and endocrine circuits may act synergistically, amplifying metabolic toxicity, immune exhaustion, and premature immunosenescence. In addition, this comorbidity thus represents the convergence of pathogen-driven and metabolism-driven inflammation, resulting in a disrupted neuroendocrine-immune dialogue and heightened susceptibility to tissue damage, particularly in the heart. Understanding the mechanistic basis of this interplay is crucial, as it highlights shared pathogenic pathways and potential molecular targets for integrated therapeutic interventions. Altogether, recognizing ChD+T2D coexistence as a mechanistic rather than merely epidemiological association provides new insights into the links between chronic infection, metabolic dysfunction, and immune aging-offering a conceptual framework for future studies aimed at restoring immune-metabolic balance and improving disease outcomes, particularly cardiac damage.